Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 ,inter alia, to consider and approve standalone unaudited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals has informed BSE that its Board of Directors will meet on Tuesday, 12th August 2025 at the company's registered office. The main agenda is to consider and approve the standalone unaudited financial results for the quarter ended 30th June 2025 (Q1 FY26). This is a standard advance intimation filed under SEBI Listing Regulations. No financial figures have been disclosed yet — actual numbers will only come after the board approves them on 12th August. The filing was signed by Ashish R. Shah, Company Secretary and Compliance Officer.
This is a routine procedural filing with no direct impact on shareholders. Investors should watch for the actual Q1 results announcement on or after 12th August 2025 for any meaningful business updates.